 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...2829303132333435363738...123124» |
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2358;
Secondary endpoints include overall response rate (ORR), overall survival (OS) and safety of the combination. Molecular biomarkers will be investigated.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Journal, Metastases: Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. (Pubmed Central) - Jul 21, 2023
The most common grade 3 to 5 TEAEs were hypertension with lenvatinib plus pembrolizumab (20%) and decreased platelet count with sunitinib (21.9%). Efficacy and safety for patients in the East Asian subset were generally similar to those of the global population, except as noted.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer (clinicaltrials.gov) - Jul 21, 2023
P2, N=25, Recruiting, Sponsor: M.D. Anderson Cancer Center
Efficacy and safety for patients in the East Asian subset were generally similar to those of the global population, except as noted. Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
- | New P4 trial: OPTI-DOSE: OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (clinicaltrials.gov) - Jul 20, 2023
P4, N=30, Not yet recruiting, Sponsor: University Medical Center Groningen
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 20, 2023
P2, N=29, Recruiting, Sponsor: Guangdong Provincial People's Hospital
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Enrollment closed, Tumor mutational burden, IO biomarker, Metastases: JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) - Jul 20, 2023
P3, N=530, Active, not recruiting, Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025 Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma. (Pubmed Central) - Jul 20, 2023
To elucidate lenvatinib-induced molecular modulation, we performed bulk RNA-sequencing and digital spatial profiling of 5 surgically resected human HCC specimens after lenvatinib treatment and 10 matched controls without any preceding therapy. Besides its direct antitumor effects, lenvatinib recruited cytotoxic GZMK+CD8 T cells in intratumor stroma by CXCL9 from tumor-associated macrophages, suggesting that lenvatinib-treated HCC is in the so-called excluded condition that can diminish ICI efficacy.
- ||| Journal, Adverse events: Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis. (Pubmed Central) - Jul 19, 2023
Selecting psychiatric AEs to non-selective RET multikinase inhibitors (sorafenib, lenvatinib, vandetanib, cabozantinib, and sunitinib)...Clinicians need to recognize and monitor these potentially fatal adverse events. If it is suitable for treatment with vandetanib, doctors should choose vandetanib for treatment.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Clinical, Metastases: According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (Twitter) - Jul 19, 2023
- |||| Monotherapy: 0/16 #TumorBoardTuesday #RCC 👨🏻🏫Mini tweetorial 8👩🏻🏫 📌TKI monotherapy after prior IO 📍2L ✨Keynote-146: lenvatinib+pembro 55.8% ORR ✨CaboPoint: cabozantinib 31.7% ORR (prior IO/IO) & 25% (prior IO/TKI) 📍3L/4L ✨Tivo-3: prior IO/TKI fail, tivozanib had 24% ORR @ChungHanLee3 (Twitter) - Jul 18, 2023
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Agree! Randomization is key in clinical trials for reliable results. Phase 2 trial ORRs can be misleading, but len/pembro combo looks promising for tumor shrinkage in frontline treatment. Still, gotta wait for phase 3 trials to know for sure about overall survival and other… https://t.co/FiXldGTvgV (Twitter) - Jul 18, 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: 15a/16 #TumorBoardTuesday 🧑🏼🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (Twitter) - Jul 18, 2023
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data: Hard to say. Certainly randomization is the great equalizer and we've been fooled before by shiny ORRs from phase 2 trials. Having said that len/pembro is particularly robust on tumor shrinkage endpoints in the front-line. (Twitter) - Jul 18, 2023
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) - Jul 17, 2023
The molecular mechanisms of lenvatinib resistance in patients with aHCC include the regulation of signaling pathways, the regulation of noncoding RNAs, the impact of the immune microenvironment, tumor stem cell activation and other mechanisms. This review aims to (1) summarize the progress of lenvatinib in treating aHCC, (2) delineate the known lenvatinib resistance mechanisms of current therapy, and (3) describe the development of therapeutic methods intended to overcome these resistance mechanisms.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. (Pubmed Central) - Jul 17, 2023
Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
- ||| volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca
Enrollment change, Combination therapy, Monotherapy, Immunomodulating, Metastases: GEMINI-Hepatobiliary: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov) - Jul 17, 2023
P2, N=180, Recruiting, Sponsor: AstraZeneca
Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy. N=120 --> 180
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients (clinicaltrials.gov) - Jul 17, 2023
P=N/A, N=98, Recruiting, Sponsor: Eisai Korea Inc.
N=120 --> 180 N=600 --> 98
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Metastases: 🗞️ Published in @TheLancetOncol and co-authored by VHIO’s @crisuarez08, results from the single-arm phase II KEYNOTE-B61 clinical trial support the use of pembrolizumab plus lenvatinib in patients with previously untreated advanced non-clear cell renal cell carcinoma. ➕… https://t.co/qUn891LZBA (Twitter) - Jul 15, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors. (Pubmed Central) - Jul 14, 2023
Herein, we discovered a series of novel quinolone-based covalent pan-FGFR inhibitors by further optimizing the lead compound (lenvatinib) under the guidance of molecular docking...The irreversible binding to target proteins was characterized by liquid chromatography and tandem mass spectrometry (LC-MS/MS). Moreover, I-5 exhibited favorable PK properties in vivo and induced significant TGI in the Huh-7 and NCI-H1581 xenograft mouse models.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Metastases: The sustained OS benefit observed with pembrolizumab and lenvatinib in the CLEAR study solidifies the doublet’s use as a preferred option for the frontline treatment of patients with advanced RCC. @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/Jmjj0bMNuC (Twitter) - Jul 14, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib. (Pubmed Central) - Jul 13, 2023
TgAb evaluation may represent a reliable surrogate marker for Tg trend in evaluating response of RAIR-DTC to treatment with lenvatinib. A multicentric study would be useful to confirm our results.
- | reozalimab (IBI318) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov) - Jul 13, 2023
P1, N=100, Recruiting, Sponsor: Hunan Province Tumor Hospital
A multicentric study would be useful to confirm our results. Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Metastases: ⭐️KEYNOTE-B61 single-arm, ph 2 trial of first-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma, 78 of 158 patients had a confirmed objective response (49%; 95% CI 41–57) @TheLancetOncol @OncoAlert @AlbigesL https://t.co/59ZG4tZHVI (Twitter) - Jul 12, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) - Jul 12, 2023
Online data analysis of LR cells showed significant differences in the immune microenvironment and drug sensitivity compared with their parental counterparts. Taken together, AKR1C1 may serve as a candidate therapeutic target for LR liver cancer patients.
- || Review, Journal: Kinase inhibitors in thyroid cancers. (Pubmed Central) - Jul 12, 2023
Dabrafenib plus trametinib for BRAF mutated anaplastic thyroid cancer provides an effective treatment option for this aggressive cancer with a dismal prognosis. In order to design the next generation of agents for thyroid cancer, future efforts will need to focus on developing a better understanding of the mechanisms of resistance to kinase inhibition including bypass signaling and escape mutations.
- Jemperli (dostarlimab-gxly) / GSK
SEMINAL: Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: a Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (Auditorium; In-Person) - Jul 12, 2023 - Abstract #IGCS2023IGCS_32;
P3
Dostarlimab+CP demonstrates PFS and OS benefits compared with PBO+CP in pts with pA/rEC despite the use of subsequent therapies. These results provide support for the use of dostarlimab+CP as standard of care in patients with pA/rEC.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer. (Pubmed Central) - Jul 11, 2023
The key to promoting the development of EC immunotherapy is to select the best patients according to the molecular classification and immunophenotype such as tumor mutation load, MMR status, pd-l1 expression, tumor infiltrating immune cells to truly achieve accurate and personalized treatment. More new and influential EC immunotherapies, such as adoptive cell immunotherapy, still need to be explored in future clinical practice.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
After a great presentation at @ASCO #ASCO23, full paper just out @TheLancetOncol Keynote B61: 🚹Non-clear cell mRCC 💊Pembrolizumab+Lenvatinib 1st line 🎯ORR:49%, CR:6% @DrChoueiri @AlbigesL @ChungHanLee3 @OncoAlert @DrYukselUrun https://t.co/pHrrelHSLb (Twitter) - Jul 11, 2023
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23 full text: https://t.co/QioxQEiKho Thanks to all who change rareRCC pts Tx! (Twitter) - Jul 11, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma. (Pubmed Central) - Jul 10, 2023
More new and influential EC immunotherapies, such as adoptive cell immunotherapy, still need to be explored in future clinical practice. No abstract available
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study. (Pubmed Central) - Jul 10, 2023
No significant differences in the incidence of grade ?3 TRAEs were reported between the two treatment groups. In conclusion, triple combination therapy with TLS improved survival with an acceptable safety profile compared with LS in patients with intermediate or advanced stage HCC.
- || rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
Review, Journal, Metastases: A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. (Pubmed Central) - Jul 10, 2023
The synergy between CMN-001 and everolimus observed in the phase 3 study provides an opportunity to design a phase 2b study building on the mechanism of action of CMN-001 and underlying immune and clinical outcomes revealed in the earlier studies. The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects.
- |||| nofazinlimab (CS1003) / CStone Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CS1003-305: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 10, 2023
P3, N=534, Active, not recruiting, Sponsor: CStone Pharmaceuticals
The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects. Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jul 10, 2023
P3, N=1069, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025 Trial completion date: Oct 2024 --> Jul 2024
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Clinical, Metastases: Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/2uj87xQ7pv (Twitter) - Jul 7, 2023
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Metastases: Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/4CP5RKH4Vq (Twitter) - Jul 7, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib. (Pubmed Central) - Jul 7, 2023
To our knowledge, this is the first case of successful proteinuria reduction with SGLT2i in a patient treated with Lenvatinib. Specific renal effects of SGLT2i seem promising and their effects on tyrosine kinase inhibitor renal adverse effects need to be validated in clinical trials involving cancer patients.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature. (Pubmed Central) - Jul 7, 2023
The primary tumour occurred in the native kidney and only focally showed biphasic morphology whereas the metastasis, among others to the transplant kidney, showed nonspecific, albeit different morphology, but both had consistent TFEB translocation. Treatment with the immune checkpoint inhibitor pembrolizumab together with the multi-kinase inhibitor lenvatinib achieved partial response 14 months after diagnosis.
- | Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov) - Jul 7, 2023
P2, N=40, Recruiting, Sponsor: Peking Union Medical College Hospital
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: A Case of Tracheoesophageal Fistula in a Non-metastatic Site During Lenvatinib Treatment for Hepatocellular Carcinoma. (Pubmed Central) - Jul 5, 2023
Treatment with the immune checkpoint inhibitor pembrolizumab together with the multi-kinase inhibitor lenvatinib achieved partial response 14 months after diagnosis. To the best of our knowledge, this is the first case report of tracheoesophageal fistula at a nonmetastatic site during lenvatinib treatment for hepatocellular carcinoma.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC (clinicaltrials.gov) - Jul 3, 2023
P4, N=50, Recruiting, Sponsor: Eisai Pharmaceuticals India Pvt. Ltd
To the best of our knowledge, this is the first case report of tracheoesophageal fistula at a nonmetastatic site during lenvatinib treatment for hepatocellular carcinoma. Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Jul 3, 2023
P4, N=50, Active, not recruiting, Sponsor: Eisai Pharmaceuticals India Pvt. Ltd
Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023 Trial completion date: Dec 2022 --> May 2024 | Trial primary completion date: Dec 2022 --> May 2024
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies. (Pubmed Central) - Jul 2, 2023
Considering systemic therapies, the currently available tyrosine kinase inhibitors (sorafenib, regorafenib, cabozantinib and lenvatinib) and monoclonal antibodies (ramucirumab and bevacizumab, in combination with the anti-PD-L1, atezolizumab) primarily target, among others, angiogenic pathways. Considering the importance of angiogenesis in the pathogenesis and treatment of liver cancer, in this paper, we aim to review the role of angiogenesis in HCC, addressing the molecular mechanisms, available antiangiogenic therapies and prognostic biomarkers in patients receiving these treatments.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022). (Pubmed Central) - Jun 30, 2023
This scientometric and visual analysis provides a comprehensive summary of the published articles on lenvatinib in HCC during 2014-2022, highlighting the research hotspots, knowledge domain, and frontiers. The results can provide insights into future research directions in this field.
- | AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. (Pubmed Central) - Jun 30, 2023
The results can provide insights into future research directions in this field. TACE combined with lenvatinib and camrelizumab is a well-tolerated modality treatment with promising efficacy for advanced HCC with PVTT.
- ||| everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Thank you @CancerTherAdvsr for featuring our article on HRQOL outcomes w 2 different starting doses of lenvatinib in combination w everolimus for previously treated RCC Grateful for this opportunity @montypal @OncJournal @DrDanielHeng @docjavip @cdanicas https://t.co/eJ3z4eA5oq (Twitter) - Jun 28, 2023
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal, Adverse events: Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis. (Pubmed Central) - Jun 28, 2023
Additionally, hypothyroidism presented a high signal, especially sunitinib, with a ROR of 107.8 (95% 37.6-308.7)...No serious hepatobiliary AEs were detected. For the specific AEs, PPES and pneumothorax were VEGFR-TKI-related AEs that presented significantly higher signals than those in the general population.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2. (Pubmed Central) - Jun 28, 2023
For the specific AEs, PPES and pneumothorax were VEGFR-TKI-related AEs that presented significantly higher signals than those in the general population. Our in
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Systemic therapy with the tyrosine kinase inhibitor lenvatinib in six patients with distant metastatic malignant melanoma (Hall D) - Jun 28, 2023 - Abstract #ADO2023ADO_156;
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Jun 28, 2023
2 appetite loss onset. This suggests that changes in FGF21 levels can be used to predict patients with a greater risk of marked appetite loss and provides insights into the mechanisms underlying lenvatinib-induced appetite loss in patients with HCC.